Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.

OBJECTIVE Cryopyrin-associated periodic syndromes (CAPS) are a group of rare autoinflammatory diseases. Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurologic, cutaneous, articular syndrome (CINCA syndrome) is the most severe phenotype, with fever, rash, articular manifestations, and neurologic and neurosensory involvement. CAPS are caused by mutations in CIAS1, the gene encoding NLRP3, which plays a critical role in interleukin-1 (IL-1) processing. Anakinra, an IL-1 receptor antagonist, has been shown to be an effective treatment; however, data on long-term efficacy and safety have been sparse. This study was undertaken to assess the long-term efficacy and safety of anakinra treatment in patients with NOMID/CINCA syndrome. METHODS We retrospectively analyzed the medical records of NOMID/CINCA syndrome patients referred to 2 centers, who had started anakinra treatment before June 2007. RESULTS There were 10 patients with NOMID/CINCA syndrome who had been treated with anakinra. The patients' ages at the time anakinra treatment was initiated ranged from 3 months to 20 years. They had been followed up for 26-42 months. Sustained efficacy in the treatment of systemic inflammation and, in some cases, neurologic involvement and growth parameters, was achieved. The dosage of anakinra required for efficacy ranged from 1 to 3 mg/kg/day in the 8 oldest patients and from 6 to 10 mg/kg/day in the 2 youngest. Residual central nervous system inflammation and deafness persisted in some patients, especially if there had been a delay in diagnosis and treatment. Secondary amyloidosis persisted in cases in which it was present at treatment initiation, but no new lesions developed. No effect on overgrowth arthropathy was observed. Adverse events consisted of mild injection-site reactions. CONCLUSION The present results indicate that anakinra treatment is effective over the long term in NOMID/CINCA syndrome. However, treatment has to be initiated before irreversible lesions develop, and, particularly in very young patients, dosage adjustment is required.

[1]  G. Yancopoulos,et al.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. , 2008, Arthritis and rheumatism.

[2]  D. Kastner,et al.  A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. , 2008, Arthritis and rheumatism.

[3]  J. Ting,et al.  Osteoblasts Express NLRP3, a Nucleotide‐Binding Domain and Leucine‐Rich Repeat Region Containing Receptor Implicated in Bacterially Induced Cell Death , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  S. Sicherer,et al.  Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition , 2007, Pediatrics.

[5]  J. McGrath,et al.  Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. , 2006, Archives of dermatology.

[6]  S. Holland,et al.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.

[7]  Takeo Tanaka,et al.  A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents. , 2006, Arthritis and rheumatism.

[8]  G. Burmester,et al.  Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonist , 2005, Annals of the rheumatic diseases.

[9]  J. Serratrice,et al.  Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. , 2005, Rheumatology.

[10]  J. Roth,et al.  The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide , 2005, Scandinavian journal of rheumatology.

[11]  A. Solinger,et al.  Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. , 2005, Arthritis and rheumatism.

[12]  G. Firestein,et al.  Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist , 2004, The Lancet.

[13]  N. Wulffraat,et al.  Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. , 2004, Arthritis and rheumatism.

[14]  G. Núñez,et al.  Cryopyrin-induced interleukin 1beta secretion in monocytic cells: enhanced activity of disease-associated mutants and requirement for ASC. , 2004, The Journal of biological chemistry.

[15]  F. Martinon,et al.  NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. , 2004, Immunity.

[16]  P. Hawkins,et al.  Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. , 2004, Arthritis and rheumatism.

[17]  P. Hawkins,et al.  Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. , 2003, The New England journal of medicine.

[18]  E. Remmers,et al.  De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. , 2002, Arthritis and rheumatism.

[19]  A. Fischer,et al.  Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. , 2002, American journal of human genetics.

[20]  R. Kolodner,et al.  Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome , 2001, Nature Genetics.

[21]  A. Prieur.  A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. , 2001, Clinical and experimental rheumatology.